CHRONIC PLAQUE PSORIASIS

This study tested a new drug called bimekizumab in 49 adults with moderate to severe plaque psoriasis. The goal was to see how well it cleared skin symptoms and how safe it was over 28 weeks. Results showed significant improvement in psoriasis severity, with the drug being genera…

This study tested a drug called bimekizumab in 435 adults with moderate to severe plaque psoriasis, a skin condition causing red, scaly patches. Participants received either bimekizumab or a placebo for 16 weeks to see if the drug could clear most of the skin symptoms. The goal w…

This study tested a drug called bimekizumab in 133 Chinese adults with moderate to severe plaque psoriasis. Participants received either the drug or a placebo for 16 weeks. The main goals were to see if the drug could clear at least 90% of psoriasis symptoms and improve skin appe…

This study tested a new drug called bimekizumab in 567 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab, a placebo, or another active drug. The main goal was to see if bimekizumab could significantly clear skin symptoms by week 16. Results…

This study tested a new drug called bimekizumab against an existing treatment (adalimumab) in 478 adults with moderate to severe plaque psoriasis. The main goal was to see how many people achieved at least 90% clearer skin after 16 weeks of treatment. The trial also looked at lon…

This study looked at the long-term safety of bimekizumab in 1,353 adults with moderate to severe plaque psoriasis. Participants who completed earlier studies received open-label bimekizumab and were monitored for side effects over time. The goal was to see how safe and tolerable …

This study tested a drug called tildrakizumab in 99 adults with moderate to severe nail psoriasis, a condition causing nail damage and pain. Participants received either the drug or a placebo for 28 weeks to see if it improved nail appearance and symptoms. The goal was to find a …

This study followed 2759 adults with moderate to severe plaque psoriasis to see how well the drug risankizumab works compared to other commonly used biologic treatments. The main goals were to measure how many people achieved 90% clearer skin and how long they stayed on their fir…

This study tested a new drug called bimekizumab against an existing drug, secukinumab, in 743 adults with moderate-to-severe plaque psoriasis. The main goal was to see which drug cleared more skin completely by week 16. Both drugs are given by injection and aim to control the dis…